Overview

Neoadjuvant Endocrine Therapy in Breast Cancer

Status:
Completed
Trial end date:
2017-07-01
Target enrollment:
Participant gender:
Summary
The study aimed to compare the duration to complete or partial response (CR/PR) and the overall response rates (ORR) after six months of neoadjuvant endocrine therapy between pre-menopausal group and post-menopausal group with highly endocrine responsive operable mammary carcinoma.
Phase:
Phase 2
Details
Lead Sponsor:
Guangdong General Hospital
Guangdong Provincial People's Hospital
Treatments:
Letrozole